GE HealthCare Technologies Inc. $GEHC Shares Acquired by Natixis Advisors LLC

Natixis Advisors LLC grew its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 2.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 585,204 shares of the company’s stock after purchasing an additional 16,723 shares during the period. Natixis Advisors LLC’s holdings in GE HealthCare Technologies were worth $47,999,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of GE HealthCare Technologies by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 52,275,767 shares of the company’s stock valued at $4,287,658,000 after purchasing an additional 267,058 shares in the last quarter. Dodge & Cox raised its stake in shares of GE HealthCare Technologies by 16.8% in the 3rd quarter. Dodge & Cox now owns 27,517,311 shares of the company’s stock valued at $2,066,550,000 after purchasing an additional 3,949,361 shares in the last quarter. Capital Research Global Investors raised its stake in shares of GE HealthCare Technologies by 25.0% in the 3rd quarter. Capital Research Global Investors now owns 24,972,556 shares of the company’s stock valued at $1,875,400,000 after purchasing an additional 4,998,154 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of GE HealthCare Technologies by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 12,112,503 shares of the company’s stock valued at $989,673,000 after purchasing an additional 37,159 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC raised its stake in shares of GE HealthCare Technologies by 17.1% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 8,432,374 shares of the company’s stock valued at $633,271,000 after purchasing an additional 1,232,828 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Activity

In other news, Director Kevin Lobo purchased 10,000 shares of the company’s stock in a transaction on Friday, May 22nd. The shares were bought at an average price of $64.18 per share, for a total transaction of $641,800.00. Following the completion of the purchase, the director owned 14,363 shares of the company’s stock, valued at $921,817.34. This trade represents a 229.20% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Peter J. Arduini purchased 4,169 shares of the company’s stock in a transaction on Thursday, April 30th. The stock was purchased at an average price of $59.92 per share, for a total transaction of $249,806.48. Following the purchase, the chief executive officer directly owned 259,424 shares of the company’s stock, valued at $15,544,686.08. This trade represents a 1.63% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 21,847 shares of company stock valued at $1,361,355 over the last quarter. Corporate insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

GEHC has been the topic of a number of recent analyst reports. Weiss Ratings lowered shares of GE HealthCare Technologies from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 15th. The Goldman Sachs Group lowered shares of GE HealthCare Technologies from a “buy” rating to a “neutral” rating and cut their target price for the company from $81.00 to $65.00 in a research note on Thursday, April 30th. HSBC cut their target price on shares of GE HealthCare Technologies from $100.00 to $90.00 in a research note on Thursday, April 30th. Citigroup dropped their price objective on shares of GE HealthCare Technologies from $80.00 to $65.00 and set a “neutral” rating on the stock in a research note on Thursday, April 30th. Finally, BTIG Research dropped their price objective on shares of GE HealthCare Technologies from $85.00 to $80.00 and set a “buy” rating on the stock in a research note on Wednesday, April 29th. Nine equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $80.21.

GE HealthCare Technologies Price Performance

GEHC opened at $62.03 on Thursday. The firm has a market cap of $28.22 billion, a price-to-earnings ratio of 14.84, a price-to-earnings-growth ratio of 1.40 and a beta of 0.74. GE HealthCare Technologies Inc. has a fifty-two week low of $58.75 and a fifty-two week high of $89.77. The company’s 50-day moving average price is $67.19 and its 200 day moving average price is $75.63. The company has a quick ratio of 0.95, a current ratio of 1.22 and a debt-to-equity ratio of 0.95.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings data on Wednesday, April 29th. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.07 by ($0.08). The business had revenue of $5.13 billion for the quarter, compared to analyst estimates of $5.04 billion. GE HealthCare Technologies had a return on equity of 20.46% and a net margin of 9.10%.GE HealthCare Technologies’s revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.01 EPS. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. As a group, sell-side analysts expect that GE HealthCare Technologies Inc. will post 4.89 earnings per share for the current year.

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.